GMP Audit for Sterile Manufacturing

What Sterile Manufacturing Audits Cover

Sterile products carry the highest risk profile because there is no opportunity to remove contamination after the product is sealed. The controls that prevent contamination must be built into the facility, the process, and the people. A GMP audit for sterile manufacturing assesses whether those controls are in place and effective.

The scope includes cleanroom design and classification, air flow and pressure differentials, personnel and material flows, environmental monitoring, aseptic technique, media fill design and execution, sterilization validation, isolator and RABS integrity, and container closure integrity.

The Regulatory Context

EU GMP Annex 1

Annex 1 of EudraLex Volume 4 covers the manufacture of sterile medicinal products. It was revised effective August 2023 and introduced the contamination control strategy as a central requirement. Section 8.123 for lyophilisers became effective in August 2024. The revision places greater emphasis on holistic contamination control, operator interventions, and the design of the facility and processes.

FDA 21 CFR 211 and Sterile Products

The FDA requires that sterile products meet cGMP requirements, including controls for sterilization, aseptic processing, and environmental monitoring.

PIC/S Annex 1

PIC/S Guide PE 009 Annex 1 aligns with the EU Annex 1 revision and is used by many authorities.

WHO GMP for Sterile Products

WHO GMP guidelines cover sterile products and include guidance on aseptic processing, environmental monitoring, and sterilization.

MHRA and Sterility Assurance

The MHRA treats sterility assurance controls as a hot topic in inspections. Contamination control strategy and aseptic practices are areas of focus.

What Audits Focus On

Contamination Control Strategy

The CCS should be documented, implemented, and supported by data. It should address facility design, equipment, personnel, utilities, and environmental monitoring. The audit should check that the CCS reflects actual operations and that it addresses operator interventions.

Cleanroom Design and Classification

Cleanroom classification, air flow patterns, pressure differentials, and airlocks. The audit should check that the design supports the required cleanliness and that classification is maintained.

Personnel and Material Flows

Movement of people and materials into and within cleanrooms. The audit should check that flows prevent contamination and cross contamination.

Environmental Monitoring

Sampling points, frequency, methods, and trend analysis. The audit should check that monitoring covers critical locations and that results are trended and acted on.

Aseptic Technique

Gowning, behavior, and interventions. The audit should check that aseptic technique is practiced and that interventions are minimized and controlled.

Media Fill Design and Execution

Media fill design, interventions, incubation, and acceptance criteria. The audit should check that media fills reflect worst case conditions.

Sterilization Validation

Moist heat, dry heat, radiation, and filtration sterilization. The audit should check that validation supports the sterilization process.

Isolator and RABS Integrity

Integrity testing, glove leak testing, and transfer ports. The audit should check that integrity is maintained and tested.

Container Closure Integrity

Integrity testing methods and acceptance criteria. The audit should check that integrity is validated and monitored.

Common Findings in Sterile Manufacturing Audits

Contamination Control Strategy That Does Not Address Interventions

Media Fills That Do Not Reflect Worst Case

Environmental Monitoring Gaps

Aseptic Technique Weaknesses

Isolator or RABS Integrity Testing Gaps

Sterilization Validation Gaps

Container Closure Integrity Testing Gaps

Introducing GxP Cellators for Sterile Manufacturing Audits

GxP Cellators provides GMP audits for sterile manufacturing with a focus on Annex 1 readiness. Our audits cover contamination control strategy, cleanroom design and classification, personnel and material flows, environmental monitoring, aseptic technique, media fill design and execution, sterilization validation, isolator and RABS integrity, and container closure integrity.

We work across FDA, EMA, Health Canada, MHRA, WHO, and PIC/S frameworks, and we adapt the audit scope to the product type and the manufacturing process. Our auditors bring regulatory inspection and industry quality experience, and we deliver clear, prioritized reports with practical remediation guidance.

We also provide pre approval inspection readiness audits and mock regulatory inspections for sterile facilities preparing for inspection.

Prepare for Annex 1 and Beyond

Visit https://www.gxpcellators.com/gmp-auditing/ for service details. Email or use https://www.gxpcellators.com/contact/ to discuss your sterile manufacturing audit.

Frequently Asked Questions About Sterile Manufacturing Audits

What is the contamination control strategy?

The CCS is a documented strategy that describes how contamination is controlled across the facility, process, and personnel. It is a central requirement of the revised Annex 1.

Why are operator interventions important?

Interventions in Grade A areas are a primary source of contamination risk. The CCS must address them, and media fills must reflect worst case interventions.

What is a media fill?

A media fill is a simulation of the aseptic process using nutrient media in place of product. It is used to demonstrate that the process can produce sterile product.